Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM W KING

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1437105327
CMS profile
155180
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$833.10

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $833.10 36

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM W KING

NPI 1437105327 · CMS profile ID 155180

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437105327?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM W KING, NPI 1437105327, CMS profile ID 155180. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437105327?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). WILLIAM W KING, NPI 1437105327, CMS profile ID 155180. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437105327?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
WILLIAM W KING, NPI 1437105327, CMS profile ID 155180, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1437105327?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $833.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $23.2712/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074847 CMS
ABBVIE INC. $8.7112/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074845 CMS
ABBVIE INC. $33.1212/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074841 CMS
ABBVIE INC. $2.8612/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074843 CMS
Celgene Corporation $16.5111/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932576945 CMS
ABBVIE INC. $13.3711/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074839 CMS
ABBVIE INC. $32.7911/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074837 CMS
ABBVIE INC. $29.5211/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074835 CMS
Daiichi Sankyo Inc. $19.7710/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930873587 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.8309/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959563759 CMS
Ironwood Pharmaceuticals, Inc $12.1909/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957928559 CMS
ABBVIE INC. $14.6009/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074833 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.2908/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959715769 CMS
ABBVIE INC. $3.8708/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074831 CMS
ABBVIE INC. $30.3308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074829 CMS
ABBVIE INC. $31.9108/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074827 CMS
ABBVIE INC. $4.9108/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074825 CMS
Gilead Sciences, Inc. $21.4708/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929494509 CMS
ABBVIE INC. $28.5208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074823 CMS
ABBVIE INC. $17.9607/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074821 CMS
Micro-tech Endoscopy USA, Inc. $16.8907/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 878552979 CMS
ABBVIE INC. $28.5206/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074819 CMS
Celgene Corporation $21.8206/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932576853 CMS
Daiichi Sankyo Inc. $20.6905/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930795307 CMS
Merck Sharp & Dohme LLC $12.2205/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944431831 CMS
ABBVIE INC. $23.8104/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074817 CMS
ABBVIE INC. $18.1804/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074815 CMS
Medtronic, Inc. $154.3604/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930716741 CMS
PFIZER INC. $14.3903/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949086313 CMS
Celgene Corporation $15.9903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932576825 CMS
Boston Scientific Corporation $48.8703/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916809927 CMS
PFIZER INC. $16.8302/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949062977 CMS
Nestle HealthCare Nutrition Inc. $23.4602/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902783567 CMS
Janssen Biotech, Inc. $12.0502/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886154105 CMS
ABBVIE INC. $13.5702/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893074813 CMS
Ironwood Pharmaceuticals, Inc $12.6501/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957926395 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $525.33 35
PY2020 $276.73 12
PY2021 $464.93 18
PY2022 $833.10 36
PY2023 $693.28 36
PY2024 $682.39 33
PY2025 $698.38 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $269,520.38 177
PY2024 Principal investigator $3,335.22 3
PY2023 Principal investigator $14,467.93 9
PY2022 Principal investigator $44,458.24 10
PY2021 Principal investigator $42,064.48 12
PY2020 Principal investigator $64,496.07 14
PY2019 Principal investigator $95,256.40 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

177 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $1,740.00 12/31/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757309
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 12/19/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757211
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 12/19/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757213
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 12/19/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757215
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 12/19/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757217
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 12/19/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757219
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 12/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757221
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 12/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757223
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 12/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757225
Principal investigator 1 Boehringer Ingelheim International GmbH $201.76 12/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757227
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 12/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757229
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 12/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757307
Principal investigator 1 Boehringer Ingelheim International GmbH $1,508.05 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757189
Principal investigator 1 Boehringer Ingelheim International GmbH $6,507.70 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757191
Principal investigator 1 Boehringer Ingelheim International GmbH $3,446.00 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757193
Principal investigator 1 Boehringer Ingelheim International GmbH $14,400.00 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757199
Principal investigator 1 Boehringer Ingelheim International GmbH $8,200.00 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757201
Principal investigator 1 Boehringer Ingelheim International GmbH $3,274.15 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757203
Principal investigator 1 Boehringer Ingelheim International GmbH $2,798.55 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757207
Principal investigator 1 Boehringer Ingelheim International GmbH $1,508.05 12/08/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757209
Principal investigator 1 Boehringer Ingelheim International GmbH $7,535.10 12/04/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757187
Principal investigator 1 Boehringer Ingelheim International GmbH $1,290.55 12/04/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757205
Principal investigator 1 Boehringer Ingelheim International GmbH $3,322.55 12/03/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757185
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 12/03/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757195
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 12/03/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757197
Principal investigator 1 Boehringer Ingelheim International GmbH $3,741.05 11/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757167
Principal investigator 1 Boehringer Ingelheim International GmbH $15,368.55 11/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757169
Principal investigator 1 Boehringer Ingelheim International GmbH $6,736.70 11/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757173
Principal investigator 1 Boehringer Ingelheim International GmbH $7,611.05 11/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757179
Principal investigator 1 Boehringer Ingelheim International GmbH $8,320.10 11/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757183
Principal investigator 1 ABBVIE INC. $656.39 11/20/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202525078
Principal investigator 1 Boehringer Ingelheim International GmbH $362.50 11/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757171
Principal investigator 1 Boehringer Ingelheim International GmbH $362.50 11/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757175
Principal investigator 1 Boehringer Ingelheim International GmbH $2,576.00 11/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757177
Principal investigator 1 Boehringer Ingelheim International GmbH $2,815.25 11/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757181
Principal investigator 1 Boehringer Ingelheim International GmbH $5,375.15 11/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757301
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 11/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757305
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 11/12/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757165
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 11/12/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757303
Principal investigator 1 Boehringer Ingelheim International GmbH $62.00 10/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757155
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757157
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 10/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757159
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 10/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757161
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 10/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757163
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.60 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757105
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757109
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757113
Principal investigator 1 Boehringer Ingelheim International GmbH $14,411.55 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757117
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757119
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757121
Principal investigator 1 Boehringer Ingelheim International GmbH $274.05 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757123
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757129
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757131
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757133
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757139
Principal investigator 1 Boehringer Ingelheim International GmbH $274.05 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757141
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757143
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757149
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 09/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757153
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757097
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757099
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757101
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757103
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757281
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757283
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757285
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 09/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757287
Principal investigator 1 Boehringer Ingelheim International GmbH $2,524.50 09/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757125
Principal investigator 1 Boehringer Ingelheim International GmbH $13,650.00 09/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757127
Principal investigator 1 Boehringer Ingelheim International GmbH $7,248.55 09/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757137
Principal investigator 1 Boehringer Ingelheim International GmbH $7,002.05 09/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757145
Principal investigator 1 Boehringer Ingelheim International GmbH $7,676.30 09/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757293
Principal investigator 1 Boehringer Ingelheim International GmbH $108.75 09/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757299
Principal investigator 1 Boehringer Ingelheim International GmbH $928.05 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757107
Principal investigator 1 Boehringer Ingelheim International GmbH $580.00 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757111
Principal investigator 1 Boehringer Ingelheim International GmbH $1,073.05 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757115
Principal investigator 1 Boehringer Ingelheim International GmbH $952.00 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757135
Principal investigator 1 Boehringer Ingelheim International GmbH $580.00 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757147
Principal investigator 1 Boehringer Ingelheim International GmbH $928.05 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757151
Principal investigator 1 Boehringer Ingelheim International GmbH $5,233.05 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757289
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757291
Principal investigator 1 Boehringer Ingelheim International GmbH $537.50 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757295
Principal investigator 1 Boehringer Ingelheim International GmbH $1,973.00 09/15/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757297
Principal investigator 1 Boehringer Ingelheim International GmbH $2,581.00 08/28/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757269
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757091
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757093
Principal investigator 1 Boehringer Ingelheim International GmbH $252.20 08/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757095
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 08/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757277
Principal investigator 1 Boehringer Ingelheim International GmbH $252.20 08/26/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757279
Principal investigator 1 Boehringer Ingelheim International GmbH $217.50 08/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757265
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757267
Principal investigator 1 Boehringer Ingelheim International GmbH $1,109.25 08/04/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757271
Principal investigator 1 Boehringer Ingelheim International GmbH $5.84 07/31/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757075
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 07/31/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757077
Principal investigator 1 Boehringer Ingelheim International GmbH $22.64 07/31/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757079
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757089
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757273
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757275
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 07/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757071
Principal investigator 1 Boehringer Ingelheim International GmbH $217.50 07/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757073
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757081
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757083
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757029
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 06/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757031
Principal investigator 1 Boehringer Ingelheim International GmbH $274.05 06/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757033
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 06/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757037
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 06/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757045
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 06/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757049
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 06/24/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757069
Principal investigator 1 Boehringer Ingelheim International GmbH $31.90 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757011
Principal investigator 1 Boehringer Ingelheim International GmbH $217.50 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757013
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757015
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757017
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757019
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757021
Principal investigator 1 Boehringer Ingelheim International GmbH $5,250.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757023
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757025
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757027
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757035
Principal investigator 1 Boehringer Ingelheim International GmbH $274.05 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757039
Principal investigator 1 Boehringer Ingelheim International GmbH $31.90 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757041
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757043
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757047
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757051
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757053
Principal investigator 1 Boehringer Ingelheim International GmbH $274.05 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757055
Principal investigator 1 Boehringer Ingelheim International GmbH $174.00 06/16/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757057
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 06/13/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757259
Principal investigator 1 Boehringer Ingelheim International GmbH $1,050.00 06/13/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757261
Principal investigator 1 Boehringer Ingelheim International GmbH $175.00 06/13/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757263
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757087
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757067
Principal investigator 1 Boehringer Ingelheim International GmbH $1,750.00 05/12/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757059
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757061
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 05/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757063
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757065
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756989
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756991
Principal investigator 1 Boehringer Ingelheim International GmbH $12,900.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756993
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756995
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756997
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756999
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757001
Principal investigator 1 Boehringer Ingelheim International GmbH $1,010.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757003
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 04/17/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757005
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757009
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757231
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757233
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757235
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757237
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757239
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757241
Principal investigator 1 Boehringer Ingelheim International GmbH $1,010.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757243
Principal investigator 1 Boehringer Ingelheim International GmbH $12,900.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757245
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 03/06/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757247
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757007
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756961
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756963
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756965
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756967
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756969
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757249
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757251
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757253
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757255
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 02/25/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220757257
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756973
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756975
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756977
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756979
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756981
Principal investigator 1 Boehringer Ingelheim International GmbH $3.37 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756983
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756985
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/14/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756987
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220757085
Principal investigator 1 ABBVIE INC. $3,009.37 01/03/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202436546
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Wilmington Gastroenterology
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220756971